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Abstract
Background: The risk/benefit of initiating ART in primary HIV infection (PHI) is unclear. The benefits are more likely to
outweigh the risks in patients with severe PHI. An accepted definition of severe PHI is, however, lacking.
Methods: CASCADE patients with HIV test interval ,6 months were classified as severe and non-severe PHI based on
whether the following traits were recorded in the first 6 months following seroconversion: severe specific pre-defined
symptoms, central nervous system-implicated illness, and $1, $2 CD4,350 (and ,500) cells/mm3. For each definition, we
used Kaplan-Meier curves and Cox survival models to compare time to AIDS/death, censoring at the earlier of last clinic visit
or 1/1/1997, when combination antiretroviral therapy (cART) became available.
Results: Among 1108 included patients mostly males (85%) infected through sex between men (71%), 366 were diagnosed
with AIDS/died. The risk of AIDS/death was significantly higher for individuals with severe symptoms, those with $1
CD4,350 cells/mm3 or $2 CD4 ,500 cells/mm3 in the first 6 months [aHR (95% confidence interval) 2.1 (1.4,3.2), 2.0
(1.5,2.7), and 2.3, (1.5–3.5) respectively]. Median [interquantile range] survival for patients with $2, $1 and no CD4,350
cells/mm3 within 6 months of seroconversion was 3.9 [2.7,6.5], 5.4 [4.5,8.4] and 8.1 [4.3,10.3] years, respectively. The
diagnosis of CNS-implicated symptoms was rare and did not appear to be prognostic.
Conclusion: One CD4 count ,350 or two ,500 cells/mm3 within 6 months of seroconversion and/or severe illness in PHI
may be useful early indicators of individuals at high risk of disease progression.
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Background
Although the virological and clinical features of primary HIV
infection (PHI) were described nearly 20 years ago [1,2], it has not
been clearly established whether and what characteristics of that
early phase are predictive of subsequent faster HIV disease
progression. The risk/benefit trade-off of initiating ART in PHI is
unclear but the benefits are more likely to outweigh the risks in
patients with severe PHI. However, an accepted definition of
severe PHI, based on clinical, virological and/or immunological
characteristics during that initial period, is lacking.
Several studies have suggested that presence of seroconversion
illness with long-lasting symptoms is associated with poorer
subsequent outcomes [3,4,5]. As some symptoms are more severe
than others with symptoms ranging from a simple flu-like
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symptoms to aseptic meningitis [6], the illness itself and its
intensity may be predictive of disease progression. In particular,
symptoms which signify the involvement of the central nervous
system (CNS), such as meningeocephalitis, are known to be life-
threatening, as demonstrated by a recent case of fatal brain
necrosis in PHI [7].
Results from observational studies on the predictive value of
immunological and virological markers in early HIV infection are
inconsistent. Although it has been shown that low levels of CD4
cell count in early HIV infection are predictive of faster disease
progression [8,9,10], to our knowledge no study has provided a
practical definition of what CD4 cell level should be considered as
low.
US guidelines for antiretroviral treatment in HIV positive
patients indicate cART as optional for patients with ongoing PHI
and for those known to have seroconverted in the past 6 months,
while European guidelines indicate optional treatment for patients
with severe seroconversion illness, although a definition of severity
is not provided [11,12]. The optimal management of patients
diagnosed during PHI, however, remains unresolved. We have,
therefore, used data from routine clinical practice of patients
diagnosed with HIV during, or shortly after HIV seroconversion,
to explore definitions of PHI severity based on clinical and
immunological features in the first 6 months following HIV
seroconversion before the initiation of cART.
Methods
Patients
We used data from CASCADE in EuroCoord (www.
EuroCoord.net), a collaboration of cohorts of patients with well-
estimated dates of HIV seroconversion in Europe, Australia,
Canada, and sub-Saharan Africa [13]. The data for this study
were pooled in 2006 and, unlike most recent updates, included
information on reported seroconversion illness and specific
symptoms. The date of HIV seroconversion, used to approximate
the date of HIV infection, was estimated by various methods: most
frequently as the midpoint between dates of the last negative and
first positive HIV antibody test results, the date of laboratory
evidence of seroconversion or the date of a seroconversion illness
(and an earlier documented negative HIV test result). For this
study we restricted to patients with laboratory evidence of
seroconversion or an HIV test interval #6 months. Patients
enrolled in cohorts not reporting information on seroconversion
illness and/or with an estimated date of HIV seroconversion after
31/12/1996, when combination antiretroviral therapy (cART)
became available, were excluded.
Ethics statement
All cohorts in CASCADE received approval from their
individual ethics review boards. Approval was also given by all
ethics review boards to pool anonymised data for analyses and
dissemination (see Appendix S1). Signed informed consent was
obtained from all patients.
Definitions of severe primary HIV infection
We explored the following definitions for PHI severity based on
clinical characteristics and CD4 measurements within 6 months of
HIV diagnosis, i.e. from the first test confirming HIV infection or
laboratory evidence of seroconversion, by considering each
definition in turn and assigning eligible individuals to whether or
not they have the respective trait:
i) clinical - severe illness.: symptomatic seroconversion which
included at least one of the following disorders judged to be
severe a priori by a panel of physicians [MF, ADL, RZ SM
personal communication]: bronchitis, pneumonia, oral
candidiasis, thrombocytopenia, viral meningitis, bacterial
meningitis, encephalitis, neuropathy, candida pharyngitis
ii) clinical - CNS involvement.: symptomatic seroconversion
which included at least one of the following disorders
indicating neurological involvement agreed by the same
panel of physicians: viral meningitis, bacterial meningitis,
encephalitis, neuropathy
iii) immunological - CD4 count ,350 cells/mm3.: at least one,
then at least two CD4 counts ,350 cells/mm3 within 6
months of HIV seroconversion
iv) immunological - CD4 count ,500 cells/mm3.: at least one,
then at least two CD4 counts ,500 cells/mm3 within 6
months of HIV seroconversion
v) combinations of clinical and immunological definitions.:
severe illness/illness with CNS involvement and at least one
CD4 count ,350/,500 cells/mm3 within 6 months of
HIV seroconversion.
Analyses assessing the predictive value of immunological
definitions requiring two CD4 cell count measurements were
restricted to patients who had at least two CD4 counts measured
within 6 months of HIV diagnosis. The cut-points for the
immunological definitions were chosen based on current guide-
lines for treatment initiation in chronic infection [11,12].
Statistical analyses
For each of the above definitions, Kaplan-Meier methods were
used to compare time to the earlier of AIDS or death for patients
with and without each trait. Follow-up was right-censored at the
earlier of the last clinic visit or, to avoid selective censoring due to
cART initiation in patients with worse prognosis, 31/12/1996.
For each definition, Cox semi-parametric regression models
were used to assess the association between each trait and risk of
AIDS/death while adjusting for the following potential confound-
ers: sex, age at HIV seroconversion and risk group. For the clinical
definitions, we also adjusted for the first recorded CD4 cell count
after seroconversion. Potential confounders were defined a priori as
variables known to be associated with both the specific trait and
HIV disease progression, but which are not on the causal pathway.
Fractional polynomial models were also fitted to explore the
relationship between CD4 cell count predictors and risk of death/
AIDS [14]. There was a non-linear age effect on survival and two
age groups based on median age at seroconversion (,30 and $30
years) were, therefore, used. All models allowed for late entry into
the risk set at the time the patient was enrolled into the constituent
cohort to minimise survivorship bias. AIDS was defined using the
European case definition, i.e. excluding a CD4 count ,200 cells/
mm3 [15]. The prognostic importance of each trait was assessed
using Wald tests from the adjusted models and the R2 index of
explained variation for censored data taking values between 0 and
1 with a higher R2 score indicating a stronger association [16].
Statistical analyses were performed with Stata 12.
Sensitivity analyses
As CD4 count is known to drop transiently at the time of HIV
seroconversion, analyses of immunological definitions were also
conducted excluding all CD4 counts collected within 4 weeks of
the estimated date of seroconversion. Moreover, since patients
with missing information on seroconversion illness symptoms or
Severe Primary HIV Infection
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CD4 count within 6 months of HIV diagnosis were excluded from
the analyses of the clinical and immunological definitions and this
missing data mechanism may not be completely at random, we
repeated the analyses imputing the trait for those with missing
values [17].
Results
Patients
Of the 17146 patients in CASCADE, 1108 were included in the
analyses while the remaining patients were excluded as follows:
11083 had an HIV test interval .6 months, 2362 seroconverted
after 31/12/1996, 2593 were enrolled in cohorts not reporting
information on seroconversion illness. The included patients were
mostly males (85%), infected through sex between men (71%) with
median [interquantile range (IQR)] first CD4 count of 511
[350,700] cells/mm3 recorded after 3.5 months [1.7,14.1] after
seroconversion and median age at seroconversion of 29 years
[24,35] (Table 1). Clinical progression occurred in 366 patients of
whom 326 developed AIDS and 40 died during 4965.6 person-
years (PY) of follow-up (incidence rate of AIDS/death 7.4/100
PY). Median [IQR] AIDS-free survival time was 8.0 (4.6,14.0)
years. As shown in Table 1, the characteristics of patients included
in the clinical and immunological definition analyses were similar
to those of the overall eligible patient population. Patients with $1
CD4 count had a median [IQR] of 2 [1,3] CD4 measurements in
the first 6 months after HIV diagnosis per patient and a median
time from HIV seroconversion to first recorded CD4 count of 2.3
months [0.8,3.7].
Clinical definitions
Among 865 patients with information on seroconversion illness,
127 (15%) reported severe symptomatic illness, with Candida
pharyngitis (35 cases), oral candidiasis (32), pneumonia (24),
bronchitis (23) and viral meningitis (21) being the most common
illnesses. Among the 738 patients without severe symptoms, 51%
reported a seroconversion illness and the remainder reported no
illness. Median [IQR] survival for patients with severe symptoms
was 6.3[3.7,-], shorter than the 8.3 [4.8,14.0] years experienced by
the remainder (p=0.003, log-rank test). After adjustment for
potential confounders, patients with severe illness experienced a
hazard of AIDS/death of 2.1 (95% CI 1.4,3.2) compared to those
without severe illness (Table 2).
Seroconversion illness with CNS involvement (21, 19 and 1
cases of viral meningitis, neuropathy and encephalitis, respectively)
was reported in 32 patients (3.7%). There was no significant
difference in survival between those with and without this trait in
univariate or adjusted analyses (Table 2). Among those with and
without the trait, 3 (9.4%) and 54 (6.5%) patients, respectively,
developed an AIDS event with neurological involvement (demen-
tia, encephalitis, toxoplasmosis or cerebral lymphoma) (p = 0.518,
Pearson x2 test).
Immunological definitions
Figure 1 represents the risk of disease progression among 740
patients with $1 CD4 count in 6 months of HIV diagnosis as a
function of the lowest recorded CD4 count in the first 6 months of
HIV diagnosis. The risk of disease progression increased as the
lowest CD4 count measured in the first 6 months decreased with a
very marked increase in risk for individuals with at least one CD4
count ,100 cells/mm3.
Table 1. Characteristics of included patients overall and separately for clinical and immunological definitions of severe primary HIV
infection (PHI).
Overall Clinical definition (known SC illness status)
Immunological definition
($1 CD4 count within 6
months of HIV SC)
N 1108 865 740
Risk category
Sex between men 789 [71%] 633 [73%] 543 [73%]
Injecting drug use 132 [12%] 73 [8%] 34 [9%]
Sex between men & women 154 [14%] 126 [15%] 105 [14%]
Other/unknown 33 [3%] 33 [3%] 28 [4%]
Sex
Female 166 [15%] 121 [14%] 97 [13%]
Age at SC
Median [IQR], years 29 [24,35] 30 [25,36] 30 [25,36]
Time first CD4 after SC
Median [IQR], months 3.5 [1.7,14.1] 3.3 [1.4,11.8] 2.4 [0.8,3.7]
First CD4 after SC
Median [IQR], cells/mm3 511 [350,700] 522 [354,702] 556 [390,740]
HIV test interval
Median [IQR], days 88 [24,135] 82 [15,132] 76 [14,126]
Year of SC
Median [IQR], calendar year 1991 [1988,1994] 1991 [1988,1994] 1992 [1989,1994]
Abbreviations: SC = seroconversion, IQR = Interquantile range.
doi:10.1371/journal.pone.0078642.t001
Severe Primary HIV Infection
PLOS ONE | www.plosone.org 3 November 2013 | Volume 8 | Issue 11 | e78642
T
a
b
le
2
.
R
is
k
o
f
A
ID
S
an
d
/o
r
d
e
at
h
ac
co
rd
in
g
to
d
e
fi
n
it
io
n
o
f
se
ve
re
p
ri
m
ar
y
H
IV
in
fe
ct
io
n
(P
H
I)
.
N
P
e
rs
o
n
-y
e
a
r
fo
ll
o
w
-
u
p
E
v
e
n
ts
M
e
d
ia
n
[I
Q
R
]
su
rv
iv
a
l
ti
m
e
,
y
e
a
rs
`
P
-v
a
lu
e
-
u
n
a
d
ju
st
e
d
m
o
d
e
l¥
H
a
z
a
rd
ra
ti
o
(9
5
%
C
I)
1
P
-v
a
lu
e
-
a
d
ju
st
e
d
fr
o
m
C
o
x
m
o
d
e
l{
R
2
(9
5
%
C
I)
C
lin
ic
a
l
d
ef
in
it
io
n
-
se
ve
re
ill
n
es
sa
Y
e
s
1
2
7
4
2
5
.1
4
1
6
.3
[3
.7
,-
]
0
.0
0
3
2
.2
(1
.4
,3
.2
)*
,
0
.0
0
1
0
.1
1
(0
.0
6
,
0
.2
0
)
N
o
7
3
8
3
4
8
3
.1
2
4
3
8
.3
[4
.8
,1
3
.9
]
1
C
lin
ic
a
l
d
ef
in
it
io
n
-
C
N
S
in
vo
lv
em
en
tb
Y
e
s
3
2
1
2
0
.1
8
-
[3
.9
,
-]
0
.9
4
3
1
.0
(0
.5
,2
.2
)*
0
.9
3
2
0
.0
9
(0
.0
5
,0
.1
9
)
N
8
3
3
3
7
8
8
.1
2
7
6
8
.2
[4
.6
,1
4
.0
]
1
Im
m
u
n
o
lo
g
ic
a
l
d
ef
in
it
io
n
-
C
D
4
,
35
0
ce
lls
/m
m
3
Y
e
s
2
0
7
6
8
0
.4
8
2
5
.1
[3
.4
,7
.9
]
,
0
.0
0
1
2
.0
(1
.5
,2
.7
)¤
,
0
.0
0
1
0
.1
0
(0
.0
5
,0
.1
9
)
N
o
5
3
3
2
1
7
1
.3
1
3
9
8
.7
[4
.8
,
1
1
.5
]
1
Im
m
u
n
o
lo
g
ic
a
l
d
ef
in
it
io
n
-
C
D
4
,
50
0
ce
lls
/m
m
3
Y
e
s
3
9
9
1
4
3
2
.5
1
5
2
5
.5
[3
.8
,9
.1
]
,
0
.0
0
1
2
.2
(1
.6
,3
.0
)¤
,
0
.0
0
1
0
.1
1
(0
.6
,0
.2
2
)
N
o
3
4
1
1
4
1
9
.2
6
9
1
0
[5
.4
,-
]
1
Im
m
u
n
o
lo
g
ic
a
l
d
ef
in
it
io
n
-
2
C
D
4
,
35
0
ce
lls
/m
m
3
e
N
o
C
D
4
co
u
n
t,
3
5
0
2
8
2
1
0
0
5
.4
7
7
8
.1
[4
.3
,1
0
.6
]
,
0
.0
0
1
1
,
0
.0
0
1
0
,0
8
(0
.0
3
,0
.2
2
)
O
n
e
C
D
4
,
3
5
0
7
3
2
6
0
.9
2
6
5
.4
[4
.5
,8
.4
]
1
.4
(0
.9
,2
.2
)
2
o
r
m
o
re
C
D
4
,
3
5
0
8
8
2
4
6
.0
3
8
3
.9
[2
.7
,6
.5
]
2
.5
(1
.6
,3
.9
)
Im
m
u
n
o
lo
g
ic
a
l
d
ef
in
it
io
n
-
2
C
D
4
,
50
0
ce
lls
/m
m
3
e
N
o
C
D
4
co
u
n
t,
5
0
0
1
5
9
5
2
0
.4
3
1
7
.5
[4
.7
,1
0
.0
]
,
0
.0
0
1
1
,
0
.0
0
1
0
.0
9
(0
.0
4
,0
.2
3
)
O
n
e
C
D
4
,
5
0
0
9
5
3
9
0
.9
3
2
6
.7
[4
.9
,1
0
.6
]
1
.1
(0
.7
,1
.9
)
2
o
r
m
o
re
C
D
4
,
5
0
0
1
8
9
6
0
1
.0
7
8
4
.8
[3
.0
,8
.4
]
2
.3
(1
.5
,3
.5
)
a
-
b
ro
n
ch
it
is
,
p
n
e
u
m
o
n
ia
,
o
ra
l
ca
n
d
id
ia
si
s,
th
ro
m
b
o
cy
to
p
e
n
ia
,
vi
ra
l
m
e
n
in
g
it
is
,
b
ac
te
ri
al
m
e
n
in
g
it
is
,
e
n
ce
p
h
al
it
is
,
n
e
u
ro
p
at
h
y,
C
an
d
id
a
p
h
ar
yn
g
it
is
.
b
-
vi
ra
l
m
e
n
in
g
it
is
,
b
ac
te
ri
al
m
e
n
in
g
it
is
,
e
n
ce
p
h
al
it
is
,
n
e
u
ro
p
at
h
y.
*A
d
ju
st
e
d
fo
r
se
x,
ri
sk
g
ro
u
p
(s
e
x
b
e
tw
e
e
n
m
e
n
,
in
je
ct
in
g
d
ru
g
u
se
,
se
x
b
e
tw
e
e
n
m
e
n
an
d
w
o
m
e
n
,
o
th
e
r/
u
n
kn
o
w
n
),
ag
e
at
H
IV
se
ro
co
n
ve
rs
io
n
(#
3
0
an
d
.
3
0
ye
ar
s)
an
d
fi
rs
t
C
D
4
co
u
n
t
(,
3
5
0
,
3
5
1
–
5
0
0
an
d
.
5
0
0
ce
lls
/m
m
3
).
¤
A
d
ju
st
e
d
fo
r
se
x,
ri
sk
g
ro
u
p
(s
e
x
b
e
tw
e
e
n
m
e
n
,
in
je
ct
in
g
d
ru
g
u
se
,
se
x
b
e
tw
e
e
n
m
e
n
an
d
w
o
m
e
n
,
o
th
e
r/
u
n
kn
o
w
n
),
ag
e
at
H
IV
se
ro
co
n
ve
rs
io
n
(#
3
0
an
d
.
3
0
ye
ar
s)
.
¥
Lo
n
g
ra
n
k
te
st
fo
r
d
if
fe
re
n
ce
in
su
rv
iv
o
r
p
ro
b
ab
ili
ti
e
s.
1
C
o
x
se
m
ip
ar
am
e
tr
ic
su
rv
iv
al
m
o
d
e
l.
{ H
e
te
ro
g
e
n
e
it
y
te
st
fo
r
ca
te
g
o
ri
ca
l
va
ri
ab
le
s.
`
T
h
e
sy
m
b
o
l
‘‘-
’’
fo
r
m
e
d
ia
n
su
rv
iv
al
ti
m
e
in
d
ic
at
e
s
th
at
fe
w
e
r
th
an
5
0
%
o
f
p
at
ie
n
ts
at
ri
sk
h
av
e
e
xp
e
ri
e
n
ce
d
th
e
e
ve
n
t
b
y
th
e
e
n
d
o
f
fo
llo
w
-u
p
.
e
A
n
al
ys
e
s
o
n
ly
in
cl
u
d
e
d
p
at
ie
n
ts
w
it
h
at
le
as
t
2
C
D
4
co
u
n
ts
m
e
as
u
re
d
in
th
e
fi
rs
t
6
m
o
n
th
s
o
f
H
IV
d
ia
g
n
o
si
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
7
8
6
4
2
.t
0
0
2
Severe Primary HIV Infection
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e78642
Among 740 patients with $1 CD4 count in 6 months of HIV
diagnosis, 207 (28%) and 399 (54%) patients experienced $1 CD4
count,350 and $1 CD4 count ,500 cells/mm3, respectively.
There was strong evidence of a survival difference between those
with and without such a CD4 value for both immunological
definitions (p,0.001) in univariable and adjusted analyses
(Table 2). The adjusted hazard ratios for those with $1 CD4
count ,350 and $1 CD4 count ,500 cells/mm3 were 2.0 (95%
CI 1.5,2.7) and 2.2 (1.6,3.0), respectively. The R2 for the adjusted
models for the two definitions suggested that the included
covariates explained 10% and 11% of the total variability in
clinical progression (Table 2).
443 patients had at least 2 CD4 measurements within 6 months
of the HIV diagnosis (180, 263 with two, and three or more
measurements, respectively). There was strong evidence of
difference in survival for patients with none (n= 282), 1 (n = 73)
and $2(n= 88) CD4 count ,350 cells/mm3 within 6 months of
HIV diagnosis with median [IQR] survival times of 8.1 [4.3,10.6],
5.4 [4.5,8.4] and 3.9 [2.7,6.5], respectively (p,0.001 log-rank
test). Similarly, patients with no, 1 and $2CD4,500 cells/mm3
had median survival times of 7.5[4.7,10.0], 6.7 [4.9,10.6] and 4.8
[3.0,8.4] years (p,0.001) and proportion alive and AIDS-free at 4
years of HIV seroconversion of 86% (95%CI 77%,92%), 80%
(67%,89%) and 60% (50%,68%), respectively.
Combination of clinical and immunological definitions
Of 604 patients with known seroconversion illness status and at
least one CD4 count recorded within 6 months of HIV diagnosis,
31 patients had a severe seroconversion illness and at least one
CD4,350 cells/mm3. Such individuals were at increased risk of
AIDS/death (HR=2.0, 1.0–3.8) compared to those with a
CD4,350 alone (Table 3). Similarly, patients with a severe
seroconversion illness and at least one CD4,500 cells/mm3
experienced 2.2 (1.3,3.6) times the hazard of clinical progression of
patients with a severe illness alone.
There was no significant difference in survival between patients
with a seroconversion illness with CNS involvement and at least
one CD4,500 cells/mm3 or at least one CD4,350 cells/mm3
(Table 3).
Sensitivity analyses
Excluding CD4 counts in the first 4 weeks of HIV seroconver-
sion or imputing PHI severity status when this was missing did not
materially change the results of the analyses (results not shown).
Discussion
In this large study of patients diagnosed in PHI, we found that
patients experiencing any of the following within 6 months of HIV
diagnosis were more likely to experience more rapid progression of
disease: one CD4 count ,350 cells/mm3, 2 CD4 counts ,500
cells/mm3, and/or experience of severe seroconversion illness (any
of bronchitis, pneumonia, oral or pharyngeal candidiasis, throm-
bocytopenia, viral meningitis, bacterial meningitis, encephalitis,
neuropathy). We found that seroconversion illness with CNS
involvement (ie, viral meningitis, bacterial meningitis, encephalitis,
and neuropathy) was rare and there was no statistical evidence to
suggest that this associated increased risk of AIDS/death, although
confidence intervals were wide.
Our regression models for each definition of severe PHI only
explained between 9 and 12% of variability in survival following
seroconversion. Thus, these should not be interpreted as
prognostic models, since other factors in primary and chronic
HIV infection, many of which are unknown, account for the
remaining variation. They suggest, however, that in a considerable
proportion of patients infected with HIV, progression of HIV
disease may already be determined in early infection.
We found that 54% and 28% of patients diagnosed in PHI had
at least one CD4 count ,500 and ,350 cells/mm3 measured in
the first 6 months, respectively. This is consistent with our previous
findings that low CD4 counts are not uncommon in PHI [18].
This study also suggests that early CD4 counts below these levels,
Figure 1. Risk of AIDS and/or death after HIV seroconversion by lowest CD4 count recorded in the first 6 months of HIV diagnosis.
The dashed line shows a relative risk of 1 for a CD4 count of 500 cells/mm3. Risk adjusted for sex, exposure category and age at HIV seroconversion.
doi:10.1371/journal.pone.0078642.g001
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especially when recorded more than once, are predictive of fast
disease progression. In particular, we found that having 2
CD4,500 cells/mm3 in the first 6 months of HIV diagnosis was
associated with a probability of being alive and AIDS-free at 4
years of HIV seroconversion of 60% (95% CI 50%,68%), lower
than the estimated 86% (77%,92%) for individuals without a
CD4,500 cells/mm3 at that time. This underlines that immuno-
logical status can rapidly deteriorate in the first months following
seroconversion in the absence of antiretroviral therapy.
HIV penetrates the CNS very early following infection and
severe CNS symptoms have been reported in that period [7,19]. It
has been postulated that neurological involvement at PHI could be
an indicator for poor prognosis and subsequent irreversible
neurological disease [20,21]. In our study there was no statistical
effect of neurological involvement in PHI on clinical progression of
HIV disease and the risk of CNS AIDS events for patients with
and without seroconversion illness with CNS involvement was
similar. Nevertheless, since the number of patients with serocon-
version illness with CNS involvement was small (32 cases), we may
have missed a significant effect of this definition of PHI severity.
The prognostic value of HIV-RNA in the first 6 months
following seroconversion is controversial and results have shown
discrepant conclusion. Whereas the prognostic value of elevated
levels of set-point HIV RNA-is well established [22,23], study
investigators have reached discordant conclusions on the predic-
tive value of HIV-RNA levels at the time of seroconversion
[2,8,9,24,25,26]. Among immunological parameters, low CD8 cell
count in early HIV infection have been shown to be correlated
with faster disease progression [27,28]. Unfortunately, we only had
limited HIV-RNA data as HIV-RNA in the pre-cART era was not
monitored routinely and CD8 cell count is not collected in
CASCADE. We were, thus, unable to explore the effect of these
markers further. Nevertheless, the advantage of our classification
based on clinical and CD4 count in early HIV infection is its
relatively simplicity and potential for use in resource limited
settings where laboratory infrastructures are lacking.
Our analyses were subject to several important limitations. First,
initial studies suggested that long lasting and intense symptoms
during PHI are associated with poorer prognosis [3,4,5]. It is
possible that a better definition of PHI severity would include also
number and duration of seroconversion symptoms. As we had no
information on the intensity and duration of symptoms we could
not explore their predictive values on risk of clinical progression.
Second, reporting of seroconversion illness is subject to recall
bias at the time of the HIV-positive test as seroconversion illnesses
are more likely to be reported by patients with worst initial
prognosis [6]. This would lead to an overestimation of the effect of
seroconversion illness on the risk of progression. Nevertheless, we
believe that our estimates are unlikely to be affected by self report
bias, since severe seroconversion illnesses as defined in this study
consisted of clinical symptoms likely to be well-documented in
patient records.
Finally, we used data collected in the pre-cART era to avoid
selective drop at cART initiation for patients with worse prognosis.
Recent studies have reported lower initial CD4 cell counts in
individuals who have seroconverted more recently [29] and faster
disease progression [30]. It is possible, therefore, that our
conclusions about the predictive value of clinical and immuno-
logical characteristics are not generalized to more recently-infected
individuals.
Initiation of cART in PHI could be beneficial to prevent rapid
progression in patients with severe PHI. The best practice for the
clinical management of patients diagnosed in PHI or early HIV
infection remains unknown and there is ongoing debate on the
value, timing and optimal duration of cART in PHI. In three
recent randomised controlled trials (RCTs) patients who received
transient cART in PHI presented longer times to CD4,350 cells/
mm3, lower viral set-point or delayed initiation of cART according
to recommendations for chronic infection [31,32,33] compared
with patients who did not receive cART in PHI. Nevertheless,
because of the limited follow-up, these trials were unable to answer
questions on the beneficial effect of transient early cART in
altering long-term disease progression. Moreover, treatment
duration in these studies was relatively short, ranging from 12–
60 weeks and it is possible that longer durations of transient cART
could be more beneficial. No study has examined whether cART
initiated in PHI should be continued long-term. The European
guidelines recommend that once it is initiated, treatment in PHI
should be lifelong [12]. Nevertheless, there is no strong scientific
basis to support this statement and unlike treatment in chronic
infection, discontinuation of transient cART in PHI has been
shown not to be associated with increased HIV morbidity and
increases in inflammatory and coagulation markers [34]. Until
consensus on the benefit and administration of treatment in PHI is
reached, these criteria could be helpful early indicators to identify
individuals at risk of rapid HIV disease progression.
In conclusion, this study suggests that one or more CD4,350
cells/mm3 and/or severe clinical seroconversion illness, may be a
useful indicator for identifying patients who are likely to benefit
from early treatment and initial close monitoring. More evidence
from RCT is needed to establish the beneficial value of treatment
initiation in PHI.
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